Biogen (BIIB) Cash from Investing Activities (2009 - 2026)

Biogen's Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$209.5 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 342.92% year-over-year to -$209.5 million; the TTM figure through Mar 2026 stood at -$1.5 billion (down 96.45% YoY), while the FY2025 annual figure was -$1.4 billion, down 71.56% from the prior year.
• Cash from Investing Activities was -$209.5 million for Q1 2026 at Biogen, up from -$1.2 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $1.7 billion in Q3 2022 to a low of -$1.7 billion in Q3 2023.
• Historically, Cash from Investing Activities has averaged -$288.5 million across 5 years, with a median of -$141.1 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities jumped 815.84% in 2022, then tumbled 6522.04% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$141.1 million in 2022, then slumped by 362.3% to -$652.3 million in 2023, then jumped by 97.15% to -$18.6 million in 2024, then sank by 6522.04% to -$1.2 billion in 2025, then jumped by 82.99% to -$209.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$209.5 million (Q1 2026), -$1.2 billion (Q4 2025), and -$35.1 million (Q3 2025), per Business Quant data.